{
    "info": {
        "nct_id": "NCT04877613",
        "official_title": "Phase I Trial of GFRα4 CAR T Cells in Adult Patients With Recurrent or Metastatic Medullary Thyroid Cancer",
        "inclusion_criteria": "1. Signed, written informed consent\n2. Male or female age ≥ 18 years\n3. Histologically or cytologically confirmed diagnosis of medullary thyroid cancer (MTC).\n4. Incurable recurrent/metastatic disease that is progressive after at least 1 prior tyrosine kinase inhibitor (TKI) containing regimen, or the patient was intolerant of or declined such therapy.\n5. Adequate organ function defined as:\n\n   1. Serum creatinine ≤ 2.5 mg/dl or estimated creatinine clearance ≥ 30 ml/min and not on dialysis.\n   2. AST ≤ 5x upper limit of normal range and total bilirubin ≤ 2.0 mg/dl; except for patients in whom hyperbilirubinemia is attributed to Gilbert's syndrome.\n   3. Left Ventricular Ejection Fraction (LVEF) ≥ 45% confirmed by ECHO/MUGA\n   4. Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and pulse oxygen &gt; 92% on room air\n6. ECOG Performance Status that is either 0 or 1.\n7. Toxicities from prior therapies must have recovered to grade ≤ 2 according to the CTCAE 5.0 criteria or to the patient's prior baseline.\n8. Patients must have evaluable disease as defined by RECIST 1.1.\n9. Subjects of reproductive potential must agree to use acceptable birth control methods.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. Evidence of active hepatitis B or hepatitis C infection. The following would not qualify as an active infection, thus would not exclude the subject from participating\n\n   1. Positive HBV serology with undetectable viral load and ongoing antiviral prophylaxis for potential HBV reactivation.\n   2. Positive HCV serology with quantitative PCR for plasma HCV RNA below the lower limit of detection, with or without concurrent antiviral HCV treatment.\n2. Any other active, uncontrolled infection.\n3. Any prior history of moderate to severe (Grade 2 or higher) pneumonitis.\n4. Subjects with chronic kidney disease with Grade 2 or higher renal impairment (eGFR or CrCl 59-30 ml/min/1.73 m2).\n5. Class III/IV cardiovascular disability according to the New York Heart Association Classification.\n6. Clinically apparent arrhythmia or arrhythmias that are not stable on medical management within two weeks of physician-investigator confirmation of eligibility.\n7. Planned concurrent treatment with systemic high dose corticosteroids. Patients may be on a stable low dose of steroids (≤10mg equivalent of prednisone). Use of inhaled steroids is allowable. Corticosteroid treatment as anti-emetic prophylaxis on the day of lymphodepleting chemotherapy administration is allowed per institutional practice.\n8. Any moderate to severe skin rash or allergies requiring systemic treatment.\n9. Receipt of immune checkpoint inhibitors within 2 months prior to physician-investigator confirmation of eligibility - Retired with Protocol Version 3.\n10. Pregnant or nursing (lactating) women.\n11. Active autoimmune disease requiring systemic immunosuppressive treatment equivalent to ≥ 10mg daily of prednisone. Patients with autoimmune neurological diseases (such as MS or Parkinson's) will be excluded.\n12. Have any history of prior or active central nervous system (CNS) involvement (e.g., leptomeningeal disease, parenchymal masses) with MTC. Screening for this (e.g., with lumbar puncture and/or brain MRI) is not required unless suspicious symptoms and/or radiographic findings are present. Subjects with calvarial metastatic disease that extends intracranially and involves the dura will be excluded, even if CSF is negative for MTC.\n13. Known seizure disorder or history of prior seizures requiring medication.\n14. History of allergy or hypersensitivity to study product excipients (human serum albumin, DMSO, and Dextran 40).",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "6. ECOG Performance Status that is either 0 or 1.",
            "criterions": [
                {
                    "exact_snippets": "ECOG Performance Status that is either 0 or 1",
                    "criterion": "ECOG Performance Status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": [
                                "0",
                                "1"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Toxicities from prior therapies must have recovered to grade ≤ 2 according to the CTCAE 5.0 criteria or to the patient's prior baseline.",
            "criterions": [
                {
                    "exact_snippets": "Toxicities from prior therapies must have recovered to grade ≤ 2 according to the CTCAE 5.0 criteria or to the patient's prior baseline.",
                    "criterion": "toxicities from prior therapies",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "CTCAE 5.0 grade"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "recovered to the patient's prior baseline"
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Patients must have evaluable disease as defined by RECIST 1.1.",
            "criterions": [
                {
                    "exact_snippets": "Patients must have evaluable disease as defined by RECIST 1.1.",
                    "criterion": "evaluable disease",
                    "requirements": [
                        {
                            "requirement_type": "definition standard",
                            "expected_value": "RECIST 1.1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Signed, written informed consent",
            "criterions": [
                {
                    "exact_snippets": "Signed, written informed consent",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "written",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Histologically or cytologically confirmed diagnosis of medullary thyroid cancer (MTC).",
            "criterions": [
                {
                    "exact_snippets": "Histologically or cytologically confirmed diagnosis of medullary thyroid cancer (MTC)",
                    "criterion": "medullary thyroid cancer (MTC) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Male or female age ≥ 18 years",
            "criterions": [
                {
                    "exact_snippets": "Male or female",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "allowed_values",
                            "expected_value": [
                                "male",
                                "female"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "age ≥ 18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Left Ventricular Ejection Fraction (LVEF) ≥ 45% confirmed by ECHO/MUGA",
            "criterions": [
                {
                    "exact_snippets": "Left Ventricular Ejection Fraction (LVEF) ≥ 45%",
                    "criterion": "Left Ventricular Ejection Fraction (LVEF)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 45,
                                "unit": "%"
                            }
                        },
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "ECHO",
                                "MUGA"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Subjects of reproductive potential must agree to use acceptable birth control methods.",
            "criterions": [
                {
                    "exact_snippets": "Subjects of reproductive potential",
                    "criterion": "reproductive potential",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must agree to use acceptable birth control methods",
                    "criterion": "use of acceptable birth control methods",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Adequate organ function defined as:",
            "criterions": [
                {
                    "exact_snippets": "Adequate organ function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. AST ≤ 5x upper limit of normal range and total bilirubin ≤ 2.0 mg/dl; except for patients in whom hyperbilirubinemia is attributed to Gilbert's syndrome.",
            "criterions": [
                {
                    "exact_snippets": "AST ≤ 5x upper limit of normal range",
                    "criterion": "AST (aspartate aminotransferase) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "x upper limit of normal range"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "total bilirubin ≤ 2.0 mg/dl",
                    "criterion": "total bilirubin level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.0,
                                "unit": "mg/dl"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "except for patients in whom hyperbilirubinemia is attributed to Gilbert's syndrome",
                    "criterion": "hyperbilirubinemia due to Gilbert's syndrome",
                    "requirements": [
                        {
                            "requirement_type": "exception",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Incurable recurrent/metastatic disease that is progressive after at least 1 prior tyrosine kinase inhibitor (TKI) containing regimen, or the patient was intolerant of or declined such therapy.",
            "criterions": [
                {
                    "exact_snippets": "Incurable recurrent/metastatic disease",
                    "criterion": "disease status",
                    "requirements": [
                        {
                            "requirement_type": "incurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "recurrence or metastasis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "progressive after at least 1 prior tyrosine kinase inhibitor (TKI) containing regimen",
                    "criterion": "disease progression after TKI therapy",
                    "requirements": [
                        {
                            "requirement_type": "progression after TKI regimen",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "number of prior TKI regimens",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "regimen"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "the patient was intolerant of or declined such therapy",
                    "criterion": "tolerance or acceptance of TKI therapy",
                    "requirements": [
                        {
                            "requirement_type": "tolerance to TKI therapy",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "acceptance of TKI therapy",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Serum creatinine ≤ 2.5 mg/dl or estimated creatinine clearance ≥ 30 ml/min and not on dialysis.",
            "criterions": [
                {
                    "exact_snippets": "Serum creatinine ≤ 2.5 mg/dl",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "mg/dl"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "estimated creatinine clearance ≥ 30 ml/min",
                    "criterion": "estimated creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "ml/min"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "not on dialysis",
                    "criterion": "dialysis",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "3. Any prior history of moderate to severe (Grade 2 or higher) pneumonitis.",
            "criterions": [
                {
                    "exact_snippets": "Any prior history of moderate to severe (Grade 2 or higher) pneumonitis",
                    "criterion": "pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Receipt of immune checkpoint inhibitors within 2 months prior to physician-investigator confirmation of eligibility - Retired with Protocol Version 3.",
            "criterions": [
                {
                    "exact_snippets": "Receipt of immune checkpoint inhibitors within 2 months prior to physician-investigator confirmation of eligibility",
                    "criterion": "receipt of immune checkpoint inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "time since last receipt",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "14. History of allergy or hypersensitivity to study product excipients (human serum albumin, DMSO, and Dextran 40).",
            "criterions": [
                {
                    "exact_snippets": "History of allergy or hypersensitivity to study product excipients (human serum albumin, DMSO, and Dextran 40)",
                    "criterion": "allergy or hypersensitivity to study product excipients",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "excipients",
                            "expected_value": [
                                "human serum albumin",
                                "DMSO",
                                "Dextran 40"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Planned concurrent treatment with systemic high dose corticosteroids. Patients may be on a stable low dose of steroids (≤10mg equivalent of prednisone). Use of inhaled steroids is allowable. Corticosteroid treatment as anti-emetic prophylaxis on the day of lymphodepleting chemotherapy administration is allowed per institutional practice.",
            "criterions": [
                {
                    "exact_snippets": "Planned concurrent treatment with systemic high dose corticosteroids.",
                    "criterion": "systemic high dose corticosteroid treatment",
                    "requirements": [
                        {
                            "requirement_type": "planned concurrent treatment",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients may be on a stable low dose of steroids (≤10mg equivalent of prednisone).",
                    "criterion": "steroid dose",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10,
                                "unit": "mg equivalent of prednisone"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Use of inhaled steroids is allowable.",
                    "criterion": "inhaled steroid use",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Corticosteroid treatment as anti-emetic prophylaxis on the day of lymphodepleting chemotherapy administration is allowed per institutional practice.",
                    "criterion": "corticosteroid use as anti-emetic prophylaxis on day of lymphodepleting chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Class III/IV cardiovascular disability according to the New York Heart Association Classification.",
            "criterions": [
                {
                    "exact_snippets": "Class III/IV cardiovascular disability according to the New York Heart Association Classification",
                    "criterion": "cardiovascular disability (NYHA classification)",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": [
                                "Class III",
                                "Class IV"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Evidence of active hepatitis B or hepatitis C infection. The following would not qualify as an active infection, thus would not exclude the subject from participating",
            "criterions": [
                {
                    "exact_snippets": "Evidence of active hepatitis B or hepatitis C infection",
                    "criterion": "hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Evidence of active hepatitis B or hepatitis C infection",
                    "criterion": "hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Any moderate to severe skin rash or allergies requiring systemic treatment.",
            "criterions": [
                {
                    "exact_snippets": "Any moderate to severe skin rash",
                    "criterion": "skin rash",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": [
                                "moderate",
                                "severe"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "allergies requiring systemic treatment",
                    "criterion": "allergies",
                    "requirements": [
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "systemic treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Positive HBV serology with undetectable viral load and ongoing antiviral prophylaxis for potential HBV reactivation.",
            "criterions": [
                {
                    "exact_snippets": "Positive HBV serology",
                    "criterion": "HBV serology",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "undetectable viral load",
                    "criterion": "HBV viral load",
                    "requirements": [
                        {
                            "requirement_type": "detectability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "ongoing antiviral prophylaxis for potential HBV reactivation",
                    "criterion": "antiviral prophylaxis for HBV reactivation",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "ongoing"
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Active autoimmune disease requiring systemic immunosuppressive treatment equivalent to ≥ 10mg daily of prednisone. Patients with autoimmune neurological diseases (such as MS or Parkinson's) will be excluded.",
            "criterions": [
                {
                    "exact_snippets": "Active autoimmune disease requiring systemic immunosuppressive treatment equivalent to ≥ 10mg daily of prednisone",
                    "criterion": "active autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "systemic immunosuppressive treatment requirement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "immunosuppressive treatment dosage",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "mg prednisone daily"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with autoimmune neurological diseases (such as MS or Parkinson's) will be excluded",
                    "criterion": "autoimmune neurological diseases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Clinically apparent arrhythmia or arrhythmias that are not stable on medical management within two weeks of physician-investigator confirmation of eligibility.",
            "criterions": [
                {
                    "exact_snippets": "Clinically apparent arrhythmia",
                    "criterion": "arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "clinical appearance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "arrhythmias that are not stable on medical management within two weeks of physician-investigator confirmation of eligibility",
                    "criterion": "arrhythmia stability on medical management",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": "<",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Subjects with chronic kidney disease with Grade 2 or higher renal impairment (eGFR or CrCl 59-30 ml/min/1.73 m2).",
            "criterions": [
                {
                    "exact_snippets": "chronic kidney disease",
                    "criterion": "chronic kidney disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Grade 2 or higher renal impairment (eGFR or CrCl 59-30 ml/min/1.73 m2)",
                    "criterion": "renal impairment",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "grade"
                            }
                        },
                        {
                            "requirement_type": "eGFR or CrCl",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 59,
                                        "unit": "ml/min/1.73 m2"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 30,
                                        "unit": "ml/min/1.73 m2"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Pregnant or nursing (lactating) women.",
            "criterions": [
                {
                    "exact_snippets": "Pregnant ... women",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "nursing (lactating) women",
                    "criterion": "nursing (lactating) status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Have any history of prior or active central nervous system (CNS) involvement (e.g., leptomeningeal disease, parenchymal masses) with MTC. Screening for this (e.g., with lumbar puncture and/or brain MRI) is not required unless suspicious symptoms and/or radiographic findings are present. Subjects with calvarial metastatic disease that extends intracranially and involves the dura will be excluded, even if CSF is negative for MTC.",
            "criterions": [
                {
                    "exact_snippets": "history of prior or active central nervous system (CNS) involvement (e.g., leptomeningeal disease, parenchymal masses) with MTC",
                    "criterion": "central nervous system (CNS) involvement with MTC",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "current_status",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "calvarial metastatic disease that extends intracranially and involves the dura will be excluded, even if CSF is negative for MTC",
                    "criterion": "calvarial metastatic disease extending intracranially and involving the dura",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. Known seizure disorder or history of prior seizures requiring medication.",
            "criterions": [
                {
                    "exact_snippets": "Known seizure disorder",
                    "criterion": "seizure disorder",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of prior seizures requiring medication",
                    "criterion": "prior seizures requiring medication",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Any other active, uncontrolled infection.",
            "criterions": [
                {
                    "exact_snippets": "Any other active, uncontrolled infection",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Positive HCV serology with quantitative PCR for plasma HCV RNA below the lower limit of detection, with or without concurrent antiviral HCV treatment.",
            "criterions": [
                {
                    "exact_snippets": "Positive HCV serology",
                    "criterion": "HCV serology",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "quantitative PCR for plasma HCV RNA below the lower limit of detection",
                    "criterion": "plasma HCV RNA (by quantitative PCR)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 0,
                                "unit": "lower limit of detection"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "with or without concurrent antiviral HCV treatment",
                    "criterion": "concurrent antiviral HCV treatment",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": "optional"
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "4. Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and pulse oxygen &gt; 92% on room air",
            "criterions": [
                {
                    "exact_snippets": "≤ Grade 1 dyspnea",
                    "criterion": "dyspnea grade",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "pulse oxygen > 92% on room air",
                    "criterion": "pulse oxygen saturation",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 92,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}